X0202 SCHEDULE 13G/A 0001315863-26-000103 0001773195 XXXXXXXX LIVE 2 Common Stock, $0.0001 par value per share 03/31/2026 0001503802 Karyopharm Therapeutics Inc. 48576U205 85 Wells Avenue 2nd Floor Newton MA 02459 Rule 13d-1(b) Affinity Asset Advisors, LLC DE 2073517 0 2073517 0 2073517 N 8.6 IA OO Michael Cho X1 2073517 0 2073517 0 2073517 N 8.6 IN HC Karyopharm Therapeutics Inc. 85 Wells Avenue, 2nd Floor, Newton, Massachusetts, 02459 Affinity Asset Advisors, LLC Michael Cho 450 Park Avenue Suite 1403 New York, NY 10022 Affinity Asset Advisors, LLC is a Delaware limited liability company, and Michael Cho is an individual and is a citizen of the United States. N IA HC The securities reported herein are directly held by Affinity Healthcare Fund, LP (the "Fund"). Affinity Asset Advisors, LLC (the "Adviser") is the investment manager of the Fund and exercises voting and investment power over the securities held directly by the Fund reported herein pursuant to an investment management agreement between the Adviser, the Fund, and the general partner of the Fund. The Adviser may be deemed to beneficially own the securities reported herein held by the Fund by virtue of its position as investment manager of the Fund. Michael Cho, the managing member of the Adviser, may be deemed a beneficial owner of the securities reported herein held by the Fund. As of March 31, 2026, the Adviser and Mr. Cho (collectively, the "Reporting Persons") beneficially own 2,073,517 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Karyopharm Therapeutics Inc. (the "Issuer"), which amount includes 1,573,517 shares of Common Stock issuable upon the exercise of warrants (the "Warrants"). The Warrants are all subject to a beneficial ownership limitation of 9.99% of the number of shares of Common Stock of the Issuer outstanding immediately after giving effect to the issuance of the shares issuable upon exercise of the Warrants (the "Beneficial Ownership Limitation"). As of March 31, 2026, the Reporting Persons beneficially own 8.6% of the Common Stock outstanding. The percentages disclosed above are based on 24,116,833 shares of Common Stock of the Issuer outstanding as of March 30, 2026, consisting of (a) the 22,543,316 shares of Common Stock of the Issuer outstanding as of March 30, 2026, as set forth in the Issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 13, 2026, and (b) 1,573,517 shares of Common Stock issuable upon the exercise of Warrants held by the Fund. As of March 31, 2026, the Reporting Persons have sole power to vote or to direct the vote of 2,073,517 shares of Common Stock, which amount includes 1,573,517 shares of Common Stock issuable upon the exercise of warrants after giving effect to the Beneficial Ownership Limitation. As of March 31, 2026, the Reporting Persons have shared power to vote or to direct the vote of 0 shares of Common Stock. As of March 31, 2026, the Reporting Persons have sole power to dispose or to direct the disposition of 2,073,517 shares of Common Stock, which amount includes 1,573,517 shares of Common Stock issuable upon the exercise of warrants after giving effect to the Beneficial Ownership Limitation. As of March 31, 2026, the Reporting Persons have shared power to dispose or to direct the disposition of 0 shares of Common Stock. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Affinity Asset Advisors, LLC /s/ Andrew Weinstein 05/14/2026 Michael Cho /s/ Michael Cho 05/14/2026